Serruys, P.W., Farooq, V., Kalesan, B., de Vries, T., Buszman, P., Linke, A., Ischinger, T., Klauss, V., Eberli, F. and Wijns, W. (2013) Improved Safety and Reduction in Stent Thrombosis Associated with Biodegradable Polymer-Based Biolimus-Eluting Stents versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients with Coronary Artery Disease: Final 5-Year Report of the LEADERS (Limus Eluted from a Durable versus ERodable Stent Coating) Randomized, Noninferiority Trial. JACC: Cardiovascular Interventions, 6, 777-789.
https://doi.org/10.1016/j.jcin.2013.04.011

has been cited by the following article:

• TITLE: Safety and Efficacy of Ultra-Thin, Biodegradable Polymer Coated Sirolimus-Eluting Supralimus-Core Stents in Real-World Patients: Outcomes at 24-Month Follow-Up

  AUTHORS: Kala Jeethender Kumar Jain, Subash Dasarapu, Sai Satish Oruganti, Jyotsna Maddury, Srinivas Bhyravavajhala, Rama Kumari Nuthalapati, Vanaparthi Satya Bharathi Lakshmi, Rajender Betham, Anil Kumar Enikapalli

  KEYWORDS: Biodegradable Polymer, Cobalt-Chromium, Coronary Artery Disease, Drug Eluting Stents, Percutaneous Coronary Intervention, Sirolimus-Eluting Stent

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.8 No.11, November 30, 2018

  ABSTRACT: Aim: The purpose of this registry was to establish long-term safety and efficacy through implantation of Supralimus-Core sirolimus-eluting stents (SES) in real-world patients with coronary artery disease (CAD). Methods:The present registry was a retrospective, singe-arm, single-centre, investigator-initiated registry. A total of 372 consecutive patients were implanted with Supralimus-Core SES between January 2015 and November 2016. The primary endpoints were major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and target vessel revascularization (TVR) at 24 months. The secondary endpoints were all-cause death and all separate components of the primary endpoint. Additional endpoints included events of stent thrombosis classified as definite, probable, and possible stent thrombosis. Follow-ups were conducted at 30-days, 6-months, 12-months and 24-months after the index procedure. Results: The mean age of the registry population was 56.3 ± 11.1 years. Males constituted 276 (74.2%) patients. Hypertensives, diabetics, alcoholics, tobacco chewers and smokers comprised 198 (53.2%), 160 (43.0%), 93 (25.0%), 91 (24.5%) and 88 (23.7%) of the registry population, respectively. The mean length and diameter of stents implanted was 19.3 ± 8.8 mm and 2.9 ± 0.3 mm, respectively. At the 24-month follow-up, MACE was reported in 14 (3.8%) patients. Cardiac death, MI, TLR and TVR was reported in 7 (1.9%), 4 (1.1%), 3 (0.8%) and 4 (1.1%) patients, respectively. Overall stent thrombosis occurred in 4 (1.1%) patients. Conclusions: The low MACE rate of 3.8% at the 24-month follow-up indicates favorable long-term results after implantation of the ultra-thin strut Supralimus-Core SES in all-comer, real-world patients.